|
|
Post by agedhippie on Aug 2, 2024 22:20:04 GMT -5
PCPs will follow the SoC and prescribe basal before they prescribe meal time insulin, just the same as endos do. So. Mike needs to get that changed. If Inhale-2 is as good as he has said he has the trial data. Abbott needs insulin prescribed earlier in the T2 life-cycle. ... If the CIPLA results are as good as he says they will only be slightly worse than Mounjaro. Abbott needs CGMs approved for non-insulin users and then they have all diabetics covered, which is what they are focused on right now. |
|
|
|
Post by agedhippie on Aug 2, 2024 22:28:21 GMT -5
And as I said it's utterly irrelevant as the patients will all be on basal and thus covered for CGMs. Icodec failing to get approved doesn't change that one bit, the CGM makers still get the sales. 6 or 8 years later??? Are you kidding me. Robert Frost does not want to wait 6 or 8 years and then have these people die in 5 years from a heart attack. Get them the afrezza day 1 and get the CGM sales too. I am pretty sure getting them afrezza day 1 will also stop the progression and many will not have the cardo issues. I am not sure what you are mean by 6 to 8 years, time to insulin today? If that's what you mean then I think you rather miss the point. Right at this moment there are a continuous stream of Type 2 patients hitting the point where they require insulin and get a CGM, there is no 6 to 8 year lag on sales. "I am pretty sure" is not the same as can be proven. Pretty sure is just opinion and you are not going to get any traction at all with opinion. Come back when there is trial data to show reduced cardio issues like they have done with GLP-1. |
|
|
|
Post by agedhippie on Aug 2, 2024 22:36:51 GMT -5
That argument persuades me, and I don’t know why it isn’t more persuasive generally. I assume and believe poorly controlled or uncontrolled BG spikes cause harm, insidiously, slowly, over time. The question is how much damage and what kind, and would Afrezza help in real life as opposed to theoretically (for which you need trial data). This is why GLP-1 pharmas have all been industriously doing trials to show GLP-1 will improve cardio and kidney risk - it's quantified so you can sell on it (you are required to have trial data or the FDA will have words with you). |
|
|
|
Post by cretin11 on Aug 3, 2024 6:09:51 GMT -5
This thread was started to commemorate hitting $6, but has now meandered off topic into a familiar debate. There are too many posts to “clean up” but if anyone wishes to continue the debate it’s easy enough to start a new thread with an appropriate title.
And hopefully our share price will recover in the meantime to where it was when uvula started this thread.
|
|
